

Advertisement

Look at one of the world's most common diseases through a much smaller lens.

[Visit RethinkObesity.com](#)

Rethink Obesity® is a registered trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2015 Novo Nordisk. All rights reserved. 1015-00028888-1 November 2015

## Pyridium (phenazopyridine hydrochloride) - Drug Summary

Gemini Laboratories, LLC

### Jump to Section

[THERAPEUTIC CLASS](#)

[DEA CLASS](#)

[ADULT DOSAGE & INDICATIONS](#)

[ADMINISTRATION](#)

[HOW SUPPLIED](#)

[View All Sections...](#)

### Related Drug Information ▼

**Pyridium**  
(phenazopyridine hydrochloride)

#### THERAPEUTIC CLASS

Urinary tract analgesic

#### DEA CLASS

RX

#### ADULT DOSAGE & INDICATIONS

##### Irritation of Lower Urinary Tract Mucosa

**Symptomatic Relief of Pain, Burning, Urgency, Frequency, and Other Discomforts Caused by Infection, Trauma, Surgery, Endoscopic Procedures, or Passage of Sounds/Catheters:**

**Usual:** 200mg tid

**Max Duration:** 2 days, when used concomitantly w/ an antibacterial agent for treatment of UTI

#### ADMINISTRATION

Oral route

Take pc

#### HOW SUPPLIED

Tab: 100mg, 200mg

#### CONTRAINDICATIONS

Renal insufficiency.

#### WARNINGS/PRECAUTIONS

D/C when symptoms are controlled. A yellowish tinge of the skin/sclera may indicate accumulation due to impaired renal excretion and the need to d/c therapy. Produces a reddish-orange discoloration of the urine and may stain fabric; staining of contact lenses reported. May interfere with urinalysis based on spectrometry or color reactions.

#### ADVERSE REACTIONS

Headache, rash, pruritus, GI disturbance, anaphylactoid-like reaction.

#### PREGNANCY AND LACTATION

Category B, safety not known in nursing.


#### MECHANISM OF ACTION

Urinary tract analgesic; has not been established. Excreted in urine where it exerts a topical analgesic effect on urinary tract mucosa.

#### PHARMACOKINETICS

**Elimination:** Urine (as much as 66% unchanged).

Advertisement



Look at one of the world's most common diseases through a much smaller lens.

[Visit RethinkObesity.com](#)

Rethink Obesity® is a registered trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2015 Novo Nordisk. All rights reserved. 1015-00028890-1 November 2015

## ASSESSMENT

---

Assess for previous hypersensitivity to the drug, renal insufficiency, cause of urinary pain, and pregnancy/nursing status.

## MONITORING

---

Monitor for control of symptoms, development of yellowish tinge of the skin/sclera, and other adverse reactions.

## PATIENT COUNSELING

---

Inform that drug produces a reddish-orange discoloration of urine and may stain fabric and contact lenses.

## STORAGE

---

20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).

[Back to top](#)

[About Us](#) | [Help](#) | [Contact Us](#) | [Order Books](#) | [Report Adverse Events](#) | [Privacy Policy](#) | [Terms of Service](#)

US-based MDs, DOs, NPs and PAs in full-time patient practice can register for free on PDR.net. PDR.net is to be used only as a reference aid. It is not intended to be a substitute for the exercise of professional judgment. You should confirm the information on the PDR.net site through independent sources and seek other professional guidance in all treatment and diagnosis decisions.

© 2015 PDR, LLC. All rights reserved.

